NIKKEI 225
26,945.67 -388.12 (-1.42%) HANG SENG
19,000.71 -517.88 (-2.65%) CRUDE OIL
65.65 -1.09 (-1.63%) GOLD FUTURES
1,980.50 +7.00 (+0.35%) DOW
32,257.75 +395.77 (+1.24%) BTC-GBP
22,592.85 -239.45 (-1.05%)
Corcept Therapeutics Incorporated (0I3Q.L)
| Previous close | 20.99 |
| Open | 20.76 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.76 - 20.76 |
| 52-week range | 20.76 - 20.76 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.07B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 24.42 |
| EPS (TTM) | 0.85 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
5 big stock buybacks: Verisk, Con Edison | Pro Recap
Here are 5 biggest share buyback announcements from the past week you may have missed on InvestingPro. Verisk Analytics (NASDAQ:VRSK) announced that it has entered into accelerated share repurchase agreements with each of Citibank, and Goldman Sachs to repurchase an aggregate of $2.5B of the company's common stock. Morgan Stanley said on Thursday it's adding a position to the company, given (1) industry-standard network effects in an attractive industry, (2) attractive valuation after the company’s return to its traditional property and casualty-focused end markets after selling non-core business segments, and (3) from a portfolio perspective, reduces the Model’s volatility and exposure to consumer discretionary while adding exposure to high-quality industrials.
- Simply Wall St.
Corcept Therapeutics Full Year 2022 Earnings: EPS Misses Expectations
Corcept Therapeutics ( NASDAQ:CORT ) Full Year 2022 Results Key Financial Results Revenue: US$401.9m (up 9.8% from FY...
- Zacks
Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
